Amrith V. Mathew

Birmingham, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Early PET response predicts the risk of relapse after 2L axi-cel in large B-cell lymphoma.

Early PET response predicts the risk of relapse after 2L axi-cel in large B-cell lymphoma.

Journal: Blood advances

Published: January 21, 2026

Early PET response predicts the risk of relapse after 2L axi-cel in large B-cell lymphoma.

Early PET response predicts the risk of relapse after 2L axi-cel in large B-cell lymphoma.

Journal: Blood advances

Published: January 21, 2026

Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival.

Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival.

Journal: British journal of haematology

Published: October 10, 2025

Outcomes of second-line axicabtagene ciloleucel for large B-cell lymphoma in the UK.

Outcomes of second-line axicabtagene ciloleucel for large B-cell lymphoma in the UK.

Journal: HemaSphere

Published: September 05, 2025

CAR T access and outcomes in large B-cell lymphoma according to ethnicity and socioeconomic deprivation in the UK.

CAR T access and outcomes in large B-cell lymphoma according to ethnicity and socioeconomic deprivation in the UK.

Journal: British journal of haematology

Published: October 10, 2024

Risk factors for CAR T-cell manufacturing failure and patient outcomes in large B-cell lymphoma: a report from the UK National CAR T Panel.

Risk factors for CAR T-cell manufacturing failure and patient outcomes in large B-cell lymphoma: a report from the UK National CAR T Panel.

Journal: Blood cancer journal

Published: August 21, 2024

Outcomes after chimeric antigen receptor T-cell therapy across large B-cell lymphoma subtypes.

Outcomes after chimeric antigen receptor T-cell therapy across large B-cell lymphoma subtypes.

Journal: Haematologica

Published: January 08, 2024

Critical care utilisation for patients receiving chimeric antigen receptor (CAR) T cell therapy in the UK.

Critical care utilisation for patients receiving chimeric antigen receptor (CAR) T cell therapy in the UK.

Journal: British journal of anaesthesia

Published: December 07, 2023

Improved COVID-19 outcomes in CAR-T patients in the age of vaccination and preemptive pharmacotherapeutics.

Improved COVID-19 outcomes in CAR-T patients in the age of vaccination and preemptive pharmacotherapeutics.

Journal: Leukemia & lymphoma

Published: August 21, 2023

Improved outcomes of large B-cell lymphoma patients treated with CD19 CAR T in the UK over time.

Improved outcomes of large B-cell lymphoma patients treated with CD19 CAR T in the UK over time.

Journal: British journal of haematology

Published: July 08, 2023

Severe presentations and high mortality from SARS-CoV-2 in patients undergoing chimeric antigen receptor (CAR-T) therapy: a UK NCCP analysis.

Severe presentations and high mortality from SARS-CoV-2 in patients undergoing chimeric antigen receptor (CAR-T) therapy: a UK NCCP analysis.

Journal: Leukemia & lymphoma

Published: April 28, 2022

A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experience.

A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experience.

Journal: British journal of haematology

Published: January 25, 2022

Showing 1-12 of 22

Last Updated: 09/26/2026